BioVaram
Category: AI in Biotech / Drug Discovery
BioVaram is an Indian deep-tech biotechnology company pioneering AI-enabled peptide design for regenerative medicine, tissue engineering, and advanced therapeutics. BioVaram was founded in 2020. The company is led by Dr. Jaganmohan Reddy. Based in Hyderabad, Telangana, India. Team size: 11-50. Total funding raised: $847K. Latest round: Seed. Key investors include ASPIRE Seed Fund (University of Hyderabad), BIRAC BIG Grant (Government of India), Bhavya Constructions, Dr. K. I. Varaprasad Reddy (Founder, Shantha Biotechnics), Manoj Namburu and Consortium.
- Founded
- 2020
- Headquarters
- Hyderabad, Telangana, India
- Team size
- 11-50
- Total funding
- $847K
Value proposition
AI-designed peptide-based alternatives to animal-derived proteins for regenerative medicine — replacing large natural proteins (320 amino acids) with precisely engineered short peptides (15 amino acids) that are more ethical, scalable, and cost-effective, while enabling rapid domestic supply (2-day delivery in India vs 6-8 weeks for imports)
Products and solutions
Dynamic Apoptosis Detection (DAD) Kit, BioSira (Atelocollagen Type I), ColQuant (Collagen Quantification Kit), ViaBlue (Cell Proliferation Assay), PepSira (Extracellular Matrix Mimics), ExoTIK (Exosome Total Isolation & Staining Kit), De Novo Cornea (bioprinted corneal implant), ExoVaram (exosome therapies), Revnostics (diagnostic platforms)
Unique value
AI-guided de novo peptide engineering that creates synthetic extracellular matrix (ECM) mimics from scratch, eliminating reliance on animal-derived biological sources and enabling trauma-free, affordable regenerative therapies
Target customer
Research laboratories, pharmaceutical companies, and academic institutions in drug discovery, tissue engineering, and regenerative medicine; biomedical researchers in India, Southeast Asia, and Europe
Industries served
Regenerative Medicine, Tissue Engineering, Drug Discovery, Diagnostics, Cell & Gene Therapy, Biomedical Research
Technology advantage
Proprietary AI/ML models for de novo peptide design; ability to engineer peptides that replicate natural ECM protein functions at 1/20th the molecular size; integrated platform spanning AI design, stem cells, exosomes, smart biomaterials, and 3D biofabrication; first-mover in AI-designed peptide-based apoptosis detection kits
How they differentiate
Combines AI-driven molecular design with clinical-grade regenerative platforms; replaces animal-derived proteins with computationally designed synthetic peptides; vertically integrated from AI peptide design through biomaterial fabrication to diagnostic kits; strong government and industry partnerships (Teijin, Telangana government); incubated at University of Hyderabad's ASPIRE-BioNEST with mentorship from Dr. K.I. Varaprasad Reddy (founder of Shantha Biotechnics)
Main competitors
Pandorum Technologies (Bengaluru, India - tissue engineering & 3D bioprinting), Eyestem (Bengaluru, India - regenerative cell therapies), Stempeutics (India - stem cell therapies)
Key partnerships
Teijin Limited (Japan) - strategic alliance for regenerative medicine products and implantable medical devices in India and Japan (Nov 2025), Government of Telangana - MoU for Centre of Excellence in Life Sciences with ₹250 crore investment commitment (Dec 2025), Japan Tissue Engineering Co., Ltd. (J-TEC, Teijin Group)
Notable customers
Research institutions and pharmaceutical companies across India and Southeast Asia using the DAD Kit, expanding into European markets
Major milestones
Founded 2020 at University of Hyderabad's ASPIRE-BioNEST, Formal operations began 2022, Top 5 Startups at BioAsia 2024, Won Maharathi Challenge 2025, Selected for Booth Visit by Prime Minister of India, Strategic alliance with Teijin Limited (Nov 2025), MoU with Telangana Government for ₹250 crore Centre of Excellence (Dec 2025), Launched first commercial product DAD Kit, Unveiled AI-driven regenerative medicine innovation at BioAsia 2026 (Feb 2026)
Market positioning
Early-stage deep-tech biotech startup positioned at the intersection of AI and regenerative medicine in India; recognized among Top 5 Startups at BioAsia 2024; winner of Maharathi Challenge 2025; selected for Booth Visit by Prime Minister of India; niche market for apoptosis detection kits valued at ~$200M globally
Geographic focus
India (primary), Southeast Asia, expanding to Europe and Japan
About Dr. Jaganmohan Reddy
PhD from Linköping University (Sweden) in tissue engineering; MSc in Molecular Biology from University of Manitoba; Research Scientist in hospital & healthcare settings; Program Organising Committee Chair and Scientific Advisory Committee member for TERMIS (Tissue Engineering and Regenerative Medicine International Society)
Latest news about BioVaram
More AI in Biotech / Drug Discovery companies
Official website: https://www.biovaram.com